Dashboard
Manage Tickers

CVAC CureVac N.V.

Nasdaq curevac.com


$ 5.32 $ -0.02 (-0.37 %)    

Friday, 31-Oct-2025 16:10:14 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.13 $ 3.02 (0.48 %)
DIA $ 475.66 $ 0.66 (0.14 %)
SPY $ 682.10 $ 2.23 (0.33 %)
TLT $ 90.09 $ -0.27 (-0.3 %)
GLD $ 368.24 $ -2.01 (-0.54 %)
$ 5.34
$ 5.35
$ 5.20 x 30
$ 5.35 x 100
$ 5.34 - $ 5.36
$ 2.37 - $ 5.72
586,751
na
1.2B
$ 1.46
$ 7.14
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
BioNTech Commences Public Exchange Offer F...
10/22/2025 10:51:57

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherap...

curevac-reports-q2-revenues-of-eur12m-lower-than-eur144m-yoy
CureVac Reports Q2 Revenues Of EUR1.2M, Lo...
08/15/2025 11:58:01

The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in J...

Core News & Articles
Curevac And GSK Have Agreed To Resolve And...
08/08/2025 09:42:31

Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit ...

biontech-narrows-losses-q2-revenue-doubles-as-vaccine-collaboration-drives-growth
BioNTech Narrows Losses, Q2 Revenue Double...
08/04/2025 14:32:30

BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.

this-trade-desk-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday
This Trade Desk Analyst Is No Longer Bulli...
06/26/2025 16:56:52

ubs-downgrades-curevac-to-neutral-lowers-price-target-to-55
UBS Downgrades CureVac to Neutral, Lowers ...
06/26/2025 15:26:53

UBS analyst Eliana Merle downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and lowers the price target from $12 to $5.5.

5-stocks-to-ride-the-german-market-rally
5 Stocks To Ride The German Market Rally
06/16/2025 19:06:25

this-sherwin-williams-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-friday
This Sherwin-Williams Analyst Is No Longer...
06/13/2025 12:39:55

jefferies-downgrades-curevac-to-hold-lowers-price-target-to-5
Jefferies Downgrades CureVac to Hold, Lowe...
06/13/2025 11:01:18

Jefferies analyst Roger Song downgrades CureVac (NASDAQ:CVAC) from Buy to Hold and lowers the price target from $7 to $5.

nasdaq-moves-higher-oracle-shares-jump-after-upbeat-q4-results
Nasdaq Moves Higher; Oracle Shares Jump Af...
06/12/2025 16:07:35

biontech-expands-mrna-cancer-portfolio-with-curevac-125-billion-all-stock-deal
BioNTech Expands mRNA Cancer Portfolio Wit...
06/12/2025 15:07:51

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

curevac-telus-international-oracle-and-other-big-stocks-moving-higher-on-thursday
CureVac, TELUS International, Oracle And O...
06/12/2025 14:50:53

Core News & Articles
BioNTech Agrees To Acquire CureVac In All-...
06/12/2025 10:59:54

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy c...

trump-administration-terminates-590-million-moderna-bird-flu-vaccine-deal-dismantling-biden-era-pandemic-preparedness-effort
Trump Administration Terminates $590 Milli...
05/29/2025 09:10:24

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, endin...

jmp-securities-reiterates-market-outperform-on-curevac-maintains-10-price-target
JMP Securities Reiterates Market Outperfor...
05/28/2025 13:25:44

JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $10 price target.

curevac-cvac-stock-rises-after-q1-update-oncology-pipeline-gains-traction
CureVac (CVAC) Stock Rises After Q1 Update...
05/20/2025 19:42:51

CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating lo...

curevac-q1-sales-94645k-miss-334m-estimate-company-exits-quarter-with-cash-and-equivalents-worth-46091m
CureVac Q1 Sales $946.45K Miss $3.34M Esti...
05/20/2025 12:08:43

CureVac reaffirmed expected cash runway into 2028,

curevac-announces-european-patent-office-confirmed-validity-of-curevacs-european-patent--ep-4-023-755-b1-subject-to-amendments-to-specify-the-scope-of-protection
CureVac Announces European Patent Office C...
05/15/2025 20:49:00

ubs-maintains-buy-on-curevac-lowers-price-target-to-12
UBS Maintains Buy on CureVac, Lowers Price...
04/30/2025 14:22:13

UBS analyst Eliana Merle maintains CureVac (NASDAQ:CVAC) with a Buy and lowers the price target from $13 to $12.

curevacs-cash-and-cash-equivalents-position-of-4817m-as-of-december-31-2024-reaffirming-expected-cash-runway-into-2028
CureVac's Cash And Cash Equivalents Positi...
04/10/2025 11:34:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION